Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adobe Systems Inc (ADBE) vs Gilead Sciences, Inc. (GILD) Price & Performance

Adobe Systems IncTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

Adobe Systems Inc vs Gilead Sciences, Inc. — how do they compare? Adobe Systems Inc trades at $263.29 (market cap $108.50B), while Gilead Sciences, Inc. trades at $136.15 (market cap $164.99B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.

ADBEGILD
Market Cap
$108.50B$164.99B
Volume
5,187,646
Sector
TechnologyHealth
52-Week High
$367.46$155.80
52-Week Low
$193.41$110.56
Enterprise Value
$109.94B$188.06B
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adobe Systems Inc

Adobe Inc. (ADBE) trades at $263.53, down 0.63% on the day, with strong fundamental performance including 29.99% net income margin and consistent earnings beats. The stock shows bullish technical signals with support at $255 and resistance at $277, while trading below the consensus price target of $248.86. Recent institutional activity shows mixed positioning amid AI competition concerns.

Adobe presents a compelling value opportunity with accelerating revenue growth and robust profitability, though facing headwinds from AI disruption fears and CEO transition. The stock's current valuation multiples appear attractive relative to historical levels, but investor sentiment remains cautious due to competitive threats in the software sector.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adobe Systems Inc

Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.

Read more on ADBE

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD